Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Chronic immunosuppressive therapy for systemic vasculitis

C A Langford1

  • 1Immunologic Diseases Section, National Institute of Allergy and Infectious Disease, National Institutes of Health, Bethesda, MD 20892, USA.

Current Opinion in Rheumatology
|January 1, 1997
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Immunoglobulin (Ig)M antibodies to proteinase 3 in granulomatosis with polyangiitis and microscopic polyangiitis.

Clinical and experimental immunology·2017
Same author

Outcomes of nonsevere relapses in antineutrophil cytoplasmic antibody-associated vasculitis treated with glucocorticoids.

Arthritis & rheumatology (Hoboken, N.J.)·2015
Same author

Rituximab for the treatment of relapses in antineutrophil cytoplasmic antibody-associated vasculitis.

Arthritis & rheumatology (Hoboken, N.J.)·2014
Same author

Clinical outcomes of remission induction therapy for severe antineutrophil cytoplasmic antibody-associated vasculitis.

Arthritis and rheumatism·2013
Same author

2012 revised International Chapel Hill Consensus Conference Nomenclature of Vasculitides.

Arthritis and rheumatism·2012
Same author

Cyclophosphamide as induction therapy for Wegener's granulomatosis and microscopic polyangiitis.

Clinical and experimental immunology·2011
Same journal

New approaches to the management of cutaneous lupus.

Current opinion in rheumatology·2026
Same journal

"Updates in chronic nonbacterial osteomyelitis: emerging insights across the age spectrum".

Current opinion in rheumatology·2026
Same journal

Difficult-to-treat, complex-to-manage, treatment-refractory spondyloarthritis: semantics or substance?

Current opinion in rheumatology·2026
Same journal

Update on IgA nephropathy: implications for treatment in IgA vasculitis: a guide for rheumatologists.

Current opinion in rheumatology·2026
Same journal

Polyarticular juvenile idiopathic arthritis: insights from genetic studies on disease risk and pathogenesis.

Current opinion in rheumatology·2026
Same journal

Immune dysregulation in children with Down syndrome: clinical implications and emerging therapies.

Current opinion in rheumatology·2026
See all related articles

Systemic vasculitis treatments improve outcomes but carry risks like pneumonia and avascular necrosis. Monitoring strategies are crucial for managing these long-term toxicities, especially with cyclophosphamide.

Area of Science:

  • Immunology
  • Rheumatology
  • Pharmacology

Background:

  • Systemic vasculitis treatments, including glucocorticoids and cytotoxic agents, have improved patient outcomes.
  • Increased patient survival highlights the growing concern of long-term treatment-related toxicities.

Purpose of the Study:

  • To review the long-term risks associated with immunosuppressive therapies for systemic vasculitis.
  • To emphasize the importance of understanding and managing treatment toxicities through strategies and monitoring.

Main Methods:

  • Literature review focusing on adverse effects of glucocorticoids and cytotoxic agents in vasculitis patients.
  • Analysis of specific toxicities such as Pneumocystis carinii pneumonia, avascular necrosis, and cyclophosphamide-induced urologic toxicity.

Related Experiment Videos

Main Results:

  • Pneumocystis carinii pneumonia is a high-mortality risk in immunosuppressed patients, preventable with prophylaxis.
  • Glucocorticoid-induced avascular necrosis causes significant morbidity, impacting daily function and employment.
  • Cyclophosphamide therapy presents risks of urologic toxicity, necessitating long-term monitoring strategies.

Conclusions:

  • Managing long-term toxicities is essential for improving the quality of life for systemic vasculitis survivors.
  • Prophylaxis and targeted monitoring strategies can mitigate severe adverse events associated with these treatments.
  • Continued research into managing treatment complications, like joint salvage procedures, is necessary.